InvestSMART

Company announcements

leave blank for all companies
leave blank for all announcements
announcements
Reset Filters
~ We have limited the announcement data displayed on our website to the past 12 months to ensure its accuracy and usefulness.
Search Results
Company Sector Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
Neuren Pharmaceuticals Limited (NEU)
ORDINARY FULLY PAID
 Health Care $1,569 Clinical Trials Update May 2007 10 May 2007 9:23AM $0.470 $12.375 risen by 2,532.98%
Neuren Pharmaceuticals Limited (NEU)
ORDINARY FULLY PAID
 Health Care $1,569 Commitments Test Entity - First Quarter Report 30 Apr 2007 3:03PM $0.430 $12.375 risen by 2,777.91%
Neuren Pharmaceuticals Limited (NEU)
ORDINARY FULLY PAID
 Health Care $1,569 Preliminary Final Report 16 Mar 2007 12:38PM $0.480 $12.375 risen by 2,478.13%
Neuren Pharmaceuticals Limited (NEU)
ORDINARY FULLY PAID
 Health Care $1,569 Further Validation of NNZ-2566 as TBI Treatment 13 Feb 2007 8:52AM $0.560 $12.375 risen by 2,109.82%
Neuren Pharmaceuticals Limited (NEU)
ORDINARY FULLY PAID
 Health Care $1,569 Commitments Test Entity - Fourth Quarter Report 31 Jan 2007 3:07PM $0.560 $12.375 risen by 2,109.82%
Neuren Pharmaceuticals Limited (NEU)
ORDINARY FULLY PAID
 Health Care $1,569 US FDA approves Phase 3 IND for Glypromate Trial 31 Jan 2007 8:28AM $0.535 $12.375 risen by 2,213.08%
Neuren Pharmaceuticals Limited (NEU)
ORDINARY FULLY PAID
 Health Care $1,569 Successful NNZ-2566 safety trial results 17 Jan 2007 8:36AM $0.510 $12.375 risen by 2,326.47%
Neuren Pharmaceuticals Limited (NEU)
ORDINARY FULLY PAID
 Health Care $1,569 Engages Burrill to progress out-licensing 19 Dec 2006 9:39AM $0.390 $12.375 risen by 3,073.08%
Neuren Pharmaceuticals Limited (NEU)
ORDINARY FULLY PAID
 Health Care $1,569 Commitments Test Entity - Third Quarter Report 31 Oct 2006 4:17PM $0.440 $12.375 risen by 2,712.50%
Neuren Pharmaceuticals Limited (NEU)
ORDINARY FULLY PAID
 Health Care $1,569 Preclinical results show cancer regression 20 Oct 2006 9:53AM $0.440 $12.375 risen by 2,712.50%
Neuren Pharmaceuticals Limited (NEU)
ORDINARY FULLY PAID
 Health Care $1,569 NNZ 2591 positive memory loss reversal results 16 Oct 2006 9:06AM $0.430 $12.375 risen by 2,777.91%
Neuren Pharmaceuticals Limited (NEU)
ORDINARY FULLY PAID
 Health Care $1,569 Positive Preclinical Results for NNZ-3006 27 Sep 2006 9:28AM $0.400 $12.375 risen by 2,993.75%
Neuren Pharmaceuticals Limited (NEU)
ORDINARY FULLY PAID
 Health Care $1,569 A$6.0 million Share placement & Share Purchase Plan 19 Sep 2006 10:03AM $0.420 $12.375 risen by 2,846.43%
Neuren Pharmaceuticals Limited (NEU)
ORDINARY FULLY PAID
 Health Care $1,569 Half Yearly Report 12 Sep 2006 8:52AM $0.420 $12.375 risen by 2,846.43%
Neuren Pharmaceuticals Limited (NEU)
ORDINARY FULLY PAID
 Health Care $1,569 Glypromate Phase 2 Trial with US Army 4 Sep 2006 9:47AM $0.430 $12.375 risen by 2,777.91%
Neuren Pharmaceuticals Limited (NEU)
ORDINARY FULLY PAID
 Health Care $1,569 Glypromate Phase 2 trial final results 22 Aug 2006 8:29AM $0.465 $12.375 risen by 2,561.29%
Neuren Pharmaceuticals Limited (NEU)
ORDINARY FULLY PAID
 Health Care $1,569 Neuren to present NNZ2566 Phase 2 Strategy 14 Aug 2006 8:31AM $0.430 $12.375 risen by 2,777.91%
Neuren Pharmaceuticals Limited (NEU)
ORDINARY FULLY PAID
 Health Care $1,569 Selects candidate for oral treatment of Parkinsons 2 Aug 2006 8:29AM $0.450 $12.375 risen by 2,650%
Neuren Pharmaceuticals Limited (NEU)
ORDINARY FULLY PAID
 Health Care $1,569 Commitments Test Entity - Second Quarter Report 31 Jul 2006 3:48PM $0.500 $12.375 risen by 2,375%
Neuren Pharmaceuticals Limited (NEU)
ORDINARY FULLY PAID
 Health Care $1,569 Further US Army results presented on NNZ-2566 29 May 2006 9:57AM $0.510 $12.375 risen by 2,326.47%
Neuren Pharmaceuticals Limited (NEU)
ORDINARY FULLY PAID
 Health Care $1,569 Granted US patent for NNZ-2566 11 May 2006 11:48AM $0.550 $12.375 risen by 2,150%
Neuren Pharmaceuticals Limited (NEU)
ORDINARY FULLY PAID
 Health Care $1,569 Commitments Test Entity - First Quarter Report 28 Apr 2006 1:25PM $0.575 $12.375 risen by 2,052.17%
Neuren Pharmaceuticals Limited (NEU)
ORDINARY FULLY PAID
 Health Care $1,569 Neuren & US Army NNZ 2566 brain seizure results 26 Apr 2006 8:30AM $0.585 $12.375 risen by 2,015.38%
Neuren Pharmaceuticals Limited (NEU)
ORDINARY FULLY PAID
 Health Care $1,569 Reports successful Phase 2 results 12 Apr 2006 9:02AM $0.605 $12.375 risen by 1,945.45%
Neuren Pharmaceuticals Limited (NEU)
ORDINARY FULLY PAID
 Health Care $1,569 Preclinical results for oral administration of NNZ-2566 22 Mar 2006 8:45AM $0.590 $12.375 risen by 1,997.46%

776 - 800 of 820 results

Page 32 of 33

  • + Company announcements and prices are delayed by at least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.